OPEN, RANDOMIZED, PARALLEL GROUP, MULTICENTER, 12-WEEK DURATION STUDY, TO COMPARE THE EFFICACY AND SAFETY OF ROSUVASTATIN (CRESTOR®) 10 MG AND 20 MG IN COMBINATION WITH EZETIMIBE 10 MG AND SIMVASTATIN 40 MG AND 80 MG IN COMBINATION WITH EZETIMIBE 10 MG (COMBINATION WITH FIXED DOSAGE) IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND CORONARY DISEASE (CHD) OR RISK EQUIVALENT TO CHD, ATHEROSCLEROSIS OR RISK OF CHD FROM 10 YEARS OLDER TO 20%.

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2007
This article has no abstract
Epistemonikos ID: f73c51c26ebc0d55017bbac9cf52b614da3692f5
First added on: Apr 16, 2025